Try our Advanced Search for more refined results
Life Sciences - February, 2016
333 articles
- Forest Fights Class Claims In Antidepressant Marketing MDL
- IRS Had Right To Adjust Guidant's Income, Court Rules
- Sterlization Device Essure Stays On While Bayer Studies Risks
- Drug Patent Battler Asks: 'What's Michelle Lee Hiding?'
- USPTO Slams Pharma Co.'s High Court Bid To Extend Patents
- Justices Leave Alone 7th Circ. Challenge To Class Standard
- Valeant Pharmaceuticals Faces New Investigation By SEC
- Fla. Nursery Wrongly Passed Over For Marijuana License
- Amgen Patent Suit Targets Sandoz's Enbrel Biosimilar
- Aggrenox Buyers Cry Foul In Pay-For-Delay Discovery Row
- Justices Won't Hear Girardi's $10M Avandia Fee Fight
- Hip Implant Recipient Says $11M Jury Award Was Correct
- Trial Pros: Proskauer's Steve Bauer
- CVS Flu Relief Nothing But A Sugar Pill, Proposed Class Says
- Cross-Agency Collaboration: A New Normal For Product Cos.
- Experts Get Voice In Lilly's $370M Canadian Patent Fight
- Walgreen Booted From Opana MDL But Promises Comeback
- Roxane Looks To Zap Litigation Threat Over Generic Fanapt
- Nu Skin Pays $47M To End Investor Row Over China Ops
- Fed. Circ. Asked To Rethink ITC Data-Blocking Order
- Drug Co. Not Covered For 'Pill Mill' Suit, 7th Circ. Told
- Supplement Maker Fights Class Cert. Revival In False Ad Suit
- FTC Backs Off Some Doc Demands In Androgel Fight
- US, EU Swap Regulatory Cooperation Offers In TTIP
- Reckitt Benckiser Wins Transfer Of NJ Wrongful Firing Suit
- Fish & Richardson Escapes DQ Bid In Cialis Patent Row
- Morgan Lewis Adds 4 K&L Gates IP Partners In Chicago
- Philly Court Urged To Consolidate Testosterone Cases
- Taxation With Representation: Skadden, MoFo, Sidley
- Fed. Circ. Finds Howmedica Polymer Patent Is Invalid
- FTC Sets Conditions For $2.2B Hikma, Boehringer Deal
- Eli Lilly Insurer Says Brazilian Pollution Suits Not Covered
- KaloBios Close To $10M Financing After Drug Rights Buy
- Shkreli Says He Won't Intimidate Witnesses In SEC Case
- Tyco Can't Delay $60M Drug Heist Suit, Judge Rules
- MusclePharm Says Insurer Ignored Policy In Coverage Denial
- 1st Circ. Charts Conservative Post-Actavis Course In Loestrin
- What A Reversal In Stryker And Halo Would Mean
- Merck Gets K-Dur Pay-For-Delay Antitrust Case Narrowed
- Law360 Life Sciences Editorial Advisory Board
- Allstate Says Urine Testing Scheme Conned It Out Of $1.3M
- Hospital's Heart-Disease Test Patents Ruled Invalid Under Alice
- J&J Unit Argues Time Bar On Risperdal Claims Should Stand
- Morgan Stanley Ties Marred $1.3B Affymetrix Deal, Suit Says
- EU Greenlights $5.5B Dental Biz Merger With Tweaks
- Pfizer Said To Save $35B In Taxes With Move To Ireland
- McKesson Drops $1.2B On Oncology Businesses
- J&J Talc Verdict Is Product Liability Game-Changer
- 5 Legal Writing Cliches Sure To Come Back And Bite You
- 5 Tips For Founding A Successful Law Firm
- A Look At FTC's Amicus Brief In Nexium
- Ex-Stiefel Exec Tells 11th Circ. Jury Instructions Fell Short
- US, Cuba Move Closer Together On Cybersecrity Issues
- Weight Loss Supplement Maker Can't Trim FTC Suit
- Costco, Apotex Get Generic Lipitor Labeling Suit Tossed
- Pharma Groups, Economists Knock Effexor Antitrust Appeal
- Kyle Bass' Coalition Gets PTAB Review Of Anacor Patents
- NIH Says Zika Vaccine Could Be Ready For Trials By Summer
- GSK, Teva Ask Justices To Take Lamictal Pay-For-Delay Case
- Silicon Valley Startup Valuations Start To Plateau
- Senate Easily Confirms Califf To Lead FDA
- J&J Unit Looks To Dodge $13.5M Pelvic Mesh Verdict
- ANDA Access Negotiations May Affect Attorney Fee Liability
- 5 Law Office Design Tips Before Moving To Latin America
- Loestrin Ruling Signals Non-Cash Deals Won't Evade Actavis
- Kyle Bass Group Gets PTAB To Eye Pozen Drug Patent
- Shareholders Win Cert. In Suit Over Tibetan Pharma Co.'s IPO
- High Court Appears Set To Relax Patent Damages Test
- FDA Warning Wire: Doc Chided For Lax Clinical Trial Screening
- Holland & Knight Snags IP Pro From Kenyon & Kenyon In NY
- Black Box Warning On Opioid-Benzo Mixing Pushed At FDA
- Trade Judge OKs Hearing In Hemophilia Drug Import Dispute
- KaloBios Seeks Speedy Approval To Buy Chagas Drug Rights
- Stock Tipper Asks 3rd Circ. To Nix SEC Pact After Newman
- Supple Says Judge Can't Sever Injunction Bid In False Ad Suit
- Actavis Says Endo Cites Wrong Precedent In False Ad Suit
- NuVasive Hit With $42M Jury Verdict Over Poaching Claims
- Genelux Founder Asks Del. Justices For Attys' Fees Award
- Valeant Plans To Restate Results In Wake Of Pharmacy Crisis
- HQ Settles Baxter's Dispute Over Arrhythmia Drug Generic
- London's Carpmaels & Ransford Adds 2 IP Pros As Partners
- J&J Slammed With $72M Verdict In Talc Cancer Case
- ResMed Pays $800M For Health Care Software Co. Brightree
- Science Or Advocacy? Expert Challenges And Peer Review
- French Antitrust Enforcement Trends You Should Know About
- Wis. Tribe Pushes Judge To Find Right To Grow Hemp
- Lee & Hayes Adds Life Sciences Partner From K&L Gates
- 1st Circ. Revives Loestrin Pay-For-Delay Suit
- AVX Wants $37.5M Greatbatch Award Axed In Patent Fight
- 9th Circ. Won't Rethink Travelers' Win In KFx Patent Row
- Enzo Can't Revive $61M Jury Win In DNA Patent Row
- Senate Clears Way For Vote On Califf As FDA Chief
- GSK Wants To Know If MDL Plaintiffs Took Generic Zofran
- SEC Speaks '16: Enforcement Agenda Goes Beyond Disclosure
- Duke Asks Fed. Circ. To Revive Claims In Treatment Patent
- Immunotherapy Biotech Syndax Sets Terms On $66M IPO
- Nicoll Davis DQ Sought In Pill Maker's Kickback Row
- Biotech Co. Says Chemist Stole Patents For Own Firm
- Medicines Co. To Pay $4.25M To Settle Stock Drop Suit
- Why Sandoz Appeal To High Court Is Important For Biosimilars
- Congressional Outlook 2016: Patents
- High Court Damages Case Could Give Patent Owners An Edge
- Dacheng Parts With Chinese Pharma Client In $6M Suit
- Dow Can't Trim 8% Interest On $455M Award During Appeal
- Feds Fear Shkreli Will Intimidate Witnesses In SEC Fraud Row
- FTC Orders Hikma To Divest Generics Rights In $5M Deal
- Fed. Circ. Pressed To Nix ITC Data-Blocking Appeal
- AstraZeneca Ducks Row Over Too-Broad Patent
- Fla. Hits Humana With Penalty Over HIV Drugs Pricing
- Florida Trader Cops To $1.2M Insider Trading Haul
- OPINION: Big Law's Perverse Incentive System
- Bard Pushes For Quick End To Hernia Patch Death Suit
- Teva Offers Antitrust Concessions For $40.5B Generics Deal
- Fed. Circ. Says Inequitable Conduct Dooms Prosthetics Patent
- AbbVie, Besins Look To Block Doc Requests In AndroGel Suit
- GSK Ruling Raises Bar For Pharma On Brand Label Warnings
- Reed Smith Reels In Ex-Fish & Richardson IP Partner In NY
- Warner Chilcott Aims To Nix Suits Alleging Generic Blocking
- Gaming Whiz Calls Shkreli An E-Sports Deadbeat In NY Suit
- More Biotech IPOs Likely To Rely On Insiders Amid Slump
- Taxation With Representation: Schulte, Skadden, Kirkland
- Chicago Defends Painkiller Claims Against Drug Cos.
- How The Zika Virus Affects Employment-Related Travel
- Resolved FCPA Enforcement Actions Drop To 10-Year Low
- Insurer Loses Bid To Avoid Tainted Heparin Defense Coverage
- Cooley Brings Back Life Sciences Pro From Hogan Lovells
- Ga. Jury Hits J&J Unit With $4.4M Verdict Over Pelvic Implant
- Chancery OKs Shareholder Deal On $5.2B NPS-Shire Sale
- SEC Takes Shot At Kaye Scholer Atty In Shkreli Civil Case
- NuVasive Didn't Infringe Medtronic Patent, Judge Says
- 3rd Circ. Agrees Doc's Words Doom Suit Over GSK's Avandia
- Real Estate Rumors: Google, Invesco, Panattoni Development
- Hyland's Halts Theory Swap In Snake Oil Suit
- 3-D Bioprinting: 5 Things Medical Device Cos. Should Know
- TriReme Asks Fed. Circ. To Nix $20M Catheter IP Suit
- Arch Wants Eli Lilly's Contamination Coverage Suit Tossed
- Shkreli's Ex-Co. OK To Pay $198K In Bonuses, Judge Says
- Fresenius Strikes $250M Deal To Settle Dialysis Drug MDL
- Patients Say Genzyme Mischaracterizes Diluted-Drug Claims
- Businesses, Profs Want Voice In Lilly's Canadian Patent Fight
- Sex-Selection Patents Upheld In $6M Jury Verdict
- Pa. High Court OKs State Farm's Med Payment Formula
- NY Orthotics Startup Discriminated Against Exec, Suit Says
- 3rd Circ. Asked To Revive Allergan Product-Hopping Suit
- Eli Lilly, Liberty Mutual Settle Contamination Coverage Suit
- Congressional Outlook 2016: Health Care
- Sandoz Seeks High Court Take On Biosimilar Law
- PTAB Pops Dr. Reddy's Bid For Reviews Of Acne Med Patent
- Wyeth, Teva Say Effexor Pay-For-Delay Suit Fell Short
- Battling Revenue Doom And Gloom With Litigation Finance
- Amgen Fights Dismissal Bid In Del. Biosimilar Drug Case
- Cherokee Nation Wants Risperdal Suit Back In State Court
- Shkreli's Ex-Drug Co. Hasn't Justified Bonuses, Judge Says
- FDA Warning Wire: Quality Of Popular Pet Products In Doubt
- Film, Music Lobbies Say ITC Can Police Online Infringement
- Whistleblower Urges 11th Circ. To Revive Fresenius FCA Row
- Nexium Ruling Could Hurt Antitrust Cases, FTC Tells 1st Circ.
- Stryker Pays $1.28B For Medical Device Maker Physio-Control
- Pfizer To Pay $785M To Settle FCA Claims Over Protonix
- The Legacy Of Justice Scalia On IP Law
- Scalia's Rapid-Fire Questioning Transformed Oral Arguments
- Justice Scalia Leaves His Mark In Biting, Clever Dissents
- Death Of Scalia Leaves High Court Docket In Limbo
- Scalia Leaves Mighty Legacy At High Court
- GOP Attys Would Likely Back Srinivasan To Replace Scalia
- Scalia's Originalism Shifted The Constitutional Debate
- Scalia Took On Gun Control, Class Actions In Top Opinions
- Supreme Court Justice Antonin Scalia Dies At 79
- USPTO Tells Fed. Circ. Ethicon's Stent IP Claims Are Invalid
- FDA Rebuffs Allergan On Generic Restasis Tests
- DFB Pharma Wants S&N To Cough Up $26.7M In Dispute
- Nobel Tells 9th Circ. To Nix $2.3M Fee Award In Implant Deal
- Apotex, Lupin Settle Paxil Infringement Fight
- GSK Shakes Diabetes Drug Row At 3rd Circ.
- CVS To Pay $8M To Settle Oxycodone Sales Row With Feds
- Deals Rumor Mill: Intercept Pharma, Barclays, Banco Poplare
- Additional Thoughts On Class Plaintiff 'Pick-Offs'
- Shkreli, Kaye Scholer Atty Say SEC Case Can't Wait
- BioScrip To Pay Shareholders $11M In Exjade Fallout
- GSK Fined $54M Over UK 'Pay-For-Delay' Deals
- Amended Rule 26's Proportionality Standard: The First 60 Days
- GSK Gets Quick No To Request To Duck Reed Smith Case
- Merck Investors Win Prelim OK Of $1B Vioxx Marketing Deal
- Sen. Murkowski Lifts 'Frankenfish' Hold On FDA Chief Nominee
- Siblings Slam Bard's Bid To Escape Hernia Patch Death Suit
- Express Scripts Counters Bid To Transfer Antitrust Suit
- Shire, Adderall Buyers Agree To Settle Pay-For-Delay Case
- ACA, Zika, Opioids Hot Topics In HHS Budget
- Philly Pelvic Mesh Verdicts Spell Trouble For J&J
- Howmedica Staves Off Suit Over Toxic Spinal Implant
- Biotechs Stumble Following $145M In Pricings
- Pharma PTAB Petitions Jump As Firms Test New Forum
- Rx. Co. Sues Law Firm For Losing Case Against Ex-Workers
- Drug Advertising On Social Media: US Vs. Canada
- FaegreBD Adds 2 Litigators To LA Office
- Endo Can't Dump $112M Painkiller Pay-For-Delay Suit
- 3rd Circ. Ruling Backs RICO Claims Against Glaxo, Court Told
- Bankrupt KaloBios Faces Fire For Employee Bonus Plan
- NJ Shareholder Suit Over Nymox's Prostate Drug Trials Tossed
- Cravath Reps Mylan In $9.9B Deal For Swedish Drugmaker
- Steptoe Adds IP Partner From Ropes & Gray
- Smartphone, Pharma Giants Dominate List Of Top IP Targets
- Hikma Chops $2.7B Boehringer Generics Offer By 20%
- Mylan Pushes 3rd Circ. To Revive Doryx Product-Hopping Suit
- PE-Backed US Foods Leads Trio Of New IPO Filings
- FDA Warning Can't Bar Fresenius Dialysis Suits, Court Told
- Investing In The Marijuana Industry: Where We Stand
- How Does Skadden Stay No. 1?
- J&J Hit With $13.5M Verdict In 2nd Philly Pelvic Mesh Trial
- Corin Hip Implant Defect Suit Nixed For Lack Of Evidence
- FDA Seeks $5.1B Budget, Including Funds For Food Safety
- Hagens Berman Loses Sanctions Appeal In Thalidomide Row
- FDA Warning Wire: Cannabis Therapy, Cattle Feed, Frozen Fish
- FDA Panel OKs Celltrion Biosimilar Of Janssen's Remicade
- Bid For Info On Suboxone Resales Is Premature, Judge Says
- Jury Ready To Decide 2nd Philly Pelvic Mesh Case
- Biotechs Pull Offerings Totaling $155M Amid Weak Markets
- 7 Bills Promoting Medical Innovation Pass Senate Committee
- Costco Slams Generic Lipitor Labeling Suit
- OPINION: The Road To Partnership Must Keep Evolving
- Shkreli Hit With Copyright Suit Over Wu-Tang Album Art
- MusclePharm Says Liberty Unquestionably Owes For SEC Probe
- Fanelli Haag Adds IP Partner From Kenyon & Kenyon
- How Pharma Cos. Can Lessen The Risk Of Gov't Action
- Kaye Scholer Atty Taps Gupta Prosecutor In Shkreli Case
- PTAB's Ax Of Stanford DNA Test Patent Backed By Fed. Circ.
- J&J Can't Slip Baby Lotion False Ad Class Action
- Don't Limit Aggrenox Pay For Delay Discovery, Judge Told
- Chancery Nixes Injunction in Feud Over Akrimax Drug Rights
- Nexium Buyers Push 1st Circ. For New Pay-For-Delay Trial
- Chamber, CEOs Back P&G In Class Cert. Protest At High Court
- FDA Tackles Opioids Amid Rare Political Pressure
- Philly Cipro, Avelox, Levaquin Cases Won't Be Consolidated
- White House Wants $1.8B To Fight Zika Virus
- Homeopathy False Ad Beef Should Stick To NY, Hyland's Says
- NJ Jury Dings Supplement Maker $1M In Contract Row
- Has Gene By Gene Unzipped TCPA Insurance Exclusions?
- GCs Name Best Of The Best Attorneys
- 8 Firms Boast The Most Client-Savvy Attorneys
- Supernus Gets Partial Win In Drug Patent Row With Actavis
- FTC Wants Patent Prosecution Docs In Androgel Fight
- Amgen Urges No Exceptions To Biosimilar Notice At Fed. Circ.
- Fed. Circ. Revives TriReme Catheter Patent Inventor Row
- 3rd Circ. Says No Rehearing Or Fees In Thalidomide Suit
- 4 Firms Set To Guide Billion-Dollar Slate Of IPOs
- PE-Backed Therapure Biopharma Delays $93M Canadian IPO
- 2nd Circ. Urged To Revive Actos Pay For Delay Row
- McDermott Taps BioTech Markets Pro For NY Office
- Fed. Circ. Affirms Validity Of Vascular Stent Patent
- ScriptPro Asks Fed. Circ. To Save Pill-Dispenser Patent
- Taxation With Representation: Kirkland, Sullivan, Norton
- 6th Circ. Told Pliva Can't Dodge FDA's Stance On Warnings
- Proportionality Ruling Raises Concerns About Rule 26 Change
- FDA Staff Back Celltrion's Remicade Biosimilar
- Astellas To Pay $13.3M To Settle Prograf Antitrust Case
- Judge In Reed Smith Suicide Case Can't Beeline To Trial: GSK
- Diet Pill Maker Can't Skirt Campbell-Ewald With Deposit
- AbbVie, Others Escape Some Testosterone Therapy Claims
- Medicare's Biosimilar Pay Policy Draws Congressional Fire
- FDA Announces Review Of Opioid Policies
- Liberty Says MusclePharm's $3M Indemnity Suit Won't Fly
- KaloBios Can Keep Control Of Bankruptcy
- Anda Pushes For W.Va. 'Pill Mill' Coverage In 11th Circ.
- Judge Takes 2nd Look At $174M 'Short And Distort' Damages
- Deals Rumor Mill: Mattel, Sharp, Ardian
- Health Care Deal Trends Emerge From JP Morgan 2016
- Clyde & Co. Snags Fasken Martineau's IP Litigation Head
- Bayer Making Progress Settling $175M R&D Tax Row With IRS
- Stanford Says Its DNA Patent Is 'Antithesis' Of Prior Art
- KemPharm Prices $75M Private Bond After Nixing Follow-On
- IRS Deduction Denial Beyond Jurisdiction, Pot Dispensary Says
- FDA's Strategy For Interoperable Medical Device Regulation
- Reps. Attack Drug Price Hikes As Silent Shkreli Tweets Insults
- Bard Mesh Patients Cite Slow MDL Pace In Bid To Move Suits
- Bayer Urges 2nd Circ. To Uphold Dismissal Of Mirena Claims
- Biogen Escapes 1 Of 4 FCA Suits Over Alleged Kickbacks
- Taylor-Wharton Wants Breathing Room For Ch. 11 Plan
- 7th Circ. Rules Out Skin-Disease Claims Against Drugmaker
- Sens. Push Pay-For-Delay Ban To Slow Drug Spending
- KaloBios Fights Trustee As Shkreli's DC Showdown Nears
- GNC, Arthritis Drug Makers Escape False Ad Suit, For Now
- Biotechs End 2016 IPO Drought With $252.8M Total Pricing
- Shkreli, Retrophin Strike $3M Deal To End Investor Suit
- 'Bogus' Diet Pill Co. Pays $43M To Settle FTC False Ad Claims
- Unexpected Uncertainty For The 340B Drug Pricing Program
- Brafman Makes Pharma Bad Boy Shkreli Take Vow of Silence
- As Signing Nears, Froman Offers Glimpse Of TPP Strategy
- Generic Co. Loses Another Round At PTAB In Zomig IP Fight
- Genentech Misstates Breast Cancer Drug Amount, Suit Says
- J&J Escapes FCA Row Over Allegedly Faulty Hip Implants
- Fresenius Wants Over 300 Cases Out Of Dialysis Drug MDL
- Endo, Lidoderm Buyers Clash Over Docs In Pay-For-Delay Suit
- FDA Warning Wire: Ipca, Dog Thyroid Pills, Compounder Attire
- Dr. Oz Sued Over 'Miracle' Fat-Burning Supplement Promotion
- CardioNet Wins $1M In Fees After MedTel Found In Contempt
- Lawmaker Details Price Hike Strategies At Turing, Valeant
- ICC Rejects Claims That Enzymotec's IPO Breached Deal
- House Falls Short On Veto Override For ACA Repeal Bill
- Cephalon Trims 1 Year Of Provigil Claims In FCA Suit
- Boston Scientific, Bard Beat $28M Pelvic Mesh Defect Suit
- Deals Rumor Mill: ChemChina, Roche Holding, Barracuda
- Shkreli Taps Celeb Defense Atty In Securities Fraud Fight
- UK Cancer Drug Developer Raises $86M In Funding Round
- Watson Labs Says Merck Contraceptive Patent Nixed By Sale
- Gilead Can't Invalidate Merck's Drug Patents In IP Fight
- Stryker Wins Sanctions After Ex-Employee Hides Evidence
- Shire Says Expert Should Speak In Adderall Antitrust Suit
- PTAB Rightly Axed Electrosurgery Patents, Fed Circ. Told
- Index Ventures Forms New Life Sciences Investment Firm
- Hagens Berman Tells 3rd Circ. Facts Are Disputed In GSK Suit
- TE Pays $895M For Permira-Backed Medical Device Maker
- Medical Device Cybersecurity: What Pharma Cos. Should Know
- CVS Hits Endo With Pay-For-Delay Suit Over Painkiller Opana
- J&J Fights Cherokee Bid To Move Risperdal Lawsuit
- Namenda Buyers Say Product Hopping Class Action Has Legs
- US Wants Trustee Or Ch. 7 For KaloBios After Shkreli Arrest
- BigLaw Brother Didn't Bias Arbitrator, 9th Circ. Told
- Boston Scientific, Bard Pelvic Mesh Case Goes To Jury
- Consumer Seeks Win In Generic Lipitor Labeling Suit
- Fed. Circ. Affirms Ruling Axing 4 Purdue OxyContin Patents
- K&L Gates Snags High-Stakes Litigator From Latham
- Egg Donors Get Pay Limits Axed With Antitrust Settlement
- Zika Virus Is Global Emergency, WHO Declares
- CVS Hit With Suit Over Misleading Dietary Supplement Label
- Dechert Adds Ex-Norton Rose Antitrust Pro To Paris Office
- Deals Rumor Mill: Sharp, Lavazza, Blackstone Group
- Fed. Circ. Told Atelvia Skepticism Shows Patent Isn't Obvious
- Kirkland & Ellis Reps Abbott In $5.8B Acquisition Of Alere
- Biotechs, Waste Biz Give IPO Pipeline A $585M Rev-Up
- High Court Again Urged To Review Part Of Arthrex IP Loss
- Whistleblower Nets $12.2M Payday In Accredo Kickback Suit
- What The Court Got Wrong About Hatch-Waxman In Alcon
- A Cautionary Tale About 'Other Acts' And Insider Trading